Objective: The purpose of the study was to evaluate the antitumor and antioxidant status of ethanolic extract of Cyperus kyllingia Endl. on Ehrlich ascites carcinoma (EAC)-treated mice.Methods: The determination of in vivo antitumor activity was performed using EAC cells inoculated mice groups (n=12). The groups were treated for 9 consecutive days with ethanolic extract of C. kyllingia (EECK) at the doses of 20 and 40 mg/kg b.w., respectively. After 24 h of the last dose, half of the mice were sacrificed and the rest were kept alive for assessment of increase in life span. The antitumor potential of EECK was assessed by evaluating tumor volume, viable and non-viable tumor cell count, tumor weight, hematological parameters, and biochemical estimations. Furthermore, antioxidant parameters were assayed by estimating liver tissue enzymes.Results: EECK showed direct cytotoxicity on EAC cell line in a dose-dependent manner. EECK exhibited significant (p<0.05) decrease in the tumor volume, viable cell count, tumor weight, and elevated the life span of EAC tumor-bearing mice. The hematological profile, biochemical estimations, and tissue antioxidant assay were reverted to normal level in EECK-treated mice.Conclusion: Experimental results revealed that EECK possesses potent antitumor and antioxidant properties. Further, research is going on to find out the active principle(s) of EECK for better understanding of mechanism of its antitumor and antioxidant activity.

In present study the methanol extract of Cyperus tegetum rhizome (MECT) was evaluated for its effect on paracetamol-induced liver damage in Wistar rats. Serum biochemical parameters viz. serum glutamine oxaloacetate transaminase (SGOT), serum glutamine pyruvate transaminase (SGPT), serum alkaline phosphatase (ALP), total serum protein, total bilirubin content and liver biochemical parameters such as thiobarbituric acid reactive substances (TBARS) and reduced glutathione content were estimated. Biochemical and histopathological observations indicated that MECT had remarkable hepatoprotective effect against paracetamol-induced liver damage in rats.

Introduction: Parenteral administration of gentamicin is a globally known therapeutic strategy for severe infections, including severe community acquired pneumonia, complex severe acute malnourishment, neonatal and pediatric sepsis. The drug is also prescribed as an ophthalmologic anti-infective. In most cases, the therapeutic course necessitates frequent bolus medication doses, lengthy hospitalization, and ongoing therapeutic monitoring; hence a qualified healthcare provider is required. Objectives: Gentamicin is a hydrophilic drug and has a short half-life, making it difficult to achieve appropriate systemic concentrations when taken parenterally. The use of innovative oral medication delivery systems is justified in this context. Furthermore, new delivery strategies can increase the membrane permeability of gentamicin. Conclusion: The current analysis provides a detailed summary of gentamicin's research history as well as several developing drug delivery strategies that have been explored. The examples included in the paper give important evidence on innovative delivery systems for gentamicin in the domain of antimicrobial investigations opening a way for upcoming therapeutics that may provide better clinical outcomes.